Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + fluorouracil + folinic acid + benmelstobart + anlotinib
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
The combination of liposomal irinotecan, fluorouracil (5-FU), folinic acid (leucovorin), benmelstobart, and anlotinib is an investigational chemoimmunotherapy and anti-angiogenic regimen. It is being evaluated primarily as a second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). This multi-drug regimen combines the cytotoxic effects of the NAL-IRI/5-FU/LV chemotherapy backbone with the immune checkpoint inhibition of benmelstobart (an anti-PD-L1 monoclonal antibody) and the multi-targeted anti-angiogenic tyrosine kinase inhibition of anlotinib. By targeting tumor cell proliferation, vascular endothelial growth factor (VEGF) pathways, and the PD-1/PD-L1 immune checkpoint, the regimen aims to overcome the highly immunosuppressive and vascular barriers characteristic of pancreatic tumors, promoting synergistic anti-tumor activity and improving patient outcomes.
- Other names
- NAL-IRI/5-FU/LV + benmelstobart + anlotinibirinotecan liposome + fluorouracil + folinic acid + benmelstobart + anlotinibirinotecan liposome + fluorouracil + leucovorin + benmelstobart + anlotinibliposomal irinotecan + 5-FU + leucovorin + benmelstobart + anlotinibliposomal irinotecan + 5-fluorouracil + leucovorin + benmelstobart + anlotinibliposomal irinotecan + fluorouracil + folinic acid + benmelstobart + anlotinibnanoliposomal irinotecan + fluorouracil + folinic acid + benmelstobart + anlotinib
02
Targets
TOP1 (DNA Topoisomerase I)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)CD274 (Programmed cell death protein 1 ligand 1)RET (Rearranged during transfection receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on liposomal irinotecan + fluorouracil + folinic acid + benmelstobart + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + fluorouracil + folinic acid + benmelstobart + anlotinib.